4th Ligase Targeting Drug Development Summit 2024

The development of mono- and bivalent degraders continues to gain traction, but biopharma faces challenges in rapidly discovering, validating, and utilizing novel E3 ligases. This leaves therapeutic opportunities untapped due to obstacles in ligase screening, structural characterization, and assaying therapeutic efficacy.

The Annual Ligase Targeting Drug Development Summit, now in its 4th year, will unite 80+ ligase experts dedicated to tackling ligase bottlenecks through data-driven presentations, technical discussions, and interactive sessions, unlocking the potential of E3 ligases for novel drug targets.

Snapshot of Expert Speakers:
Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics
Jennifer Johnston, Co-Founder and Chief Executive Officer, NysnoBio
Marc Scanio, Principal Research Scientist, Abbvie
Oscar Huang, Associate Director, Biophysics, Lyterian Therapeutics
Peter Gareiss, Research Investigator, Arvinas
Yongli Shan, Associate Director- Discovery Biology, Vicinitas Therapeutics

Explore the full 3-day agenda here - https://ter.li/LigaseAgenda2024